Literature DB >> 21427496

Antineutrophil cytoplasmic antibodies in patients with pulmonary tuberculosis.

Roya Sherkat1, Kamyar Mostafavizadeh, Lale Zeydabadi, Parisa Shoaei, Sodabeh Rostami.   

Abstract

BACKGROUND: Mycobacterium tuberculosis is a major cause of mortality and morbidity worldwide. Infection with this bacterium is known to induce the development of autoantibodies of which a few are also known to be diagnostic markers for some other diseases. Antineutrophil Cytoplasmic Antibodies (ANCA's) are among those autoantibodies used in clinical setting for diagnosing systemic vasculitic syndromes. Multiple studies investigated ANCA positivity in diseases other than small vessel vasculitis.
OBJECTIVE: This study was performed to determine the prevalence of ANCA in pulmonary tuberculosis (TB) which may lead to the false diagnosis of Wegener's granulomatosis (WG) or vice versa.
METHODS: In a case-control study, 32 consecutive smear positive pulmonary TB patients and 32 normal individuals were studied. All cases and controls were screened for ANCA by indirect immunofluorescent assay (IIF), and MPO and PR3 were also tested by ELISA.
RESULTS: A prenuclear pattern (P-ANCA) was detected in 25% of the cases and 6.25% of the controls and a cytoplasmic pattern (C-ANCA) was deserved in 3.1% of both the cases and the controls by IIF assay. ANCA specificities tested by ELISA in cases revealed that 75% of the cases had anti-MPO and 12.5% had anti-PR3, while in the in controls, 3.12% had anti-MPO and none had anti-PR3. The positive ANCA significantly correlated with TB (p<0.01).
CONCLUSION: ANCA's may be observed in both TB and systemic vasculitic syndromes such as WG. Tuberculosis and WG share some clinical features. Therefore, in countries with a high prevalence of TB, one has to distinguish between these two diseases especially when no sign of extrapulmonary involvement is observed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21427496     DOI: IJIv8i1A7

Source DB:  PubMed          Journal:  Iran J Immunol        ISSN: 1735-1383            Impact factor:   1.603


  7 in total

1.  Anti-PR3 and anti-MPO antibodies are not present in sera of patients with pulmonary tuberculosis.

Authors:  I Lima; R C Oliveira; M S Cabral; A Atta; S Marchi; E Reis; M G Reis; L Barbosa; M B Santiago
Journal:  Rheumatol Int       Date:  2014-04-10       Impact factor: 2.631

2.  The effect of anti-tuberculosis treatment on levels of anti-phospholipid and anti-neutrophil cytoplasmatic antibodies in patients with active tuberculosis.

Authors:  Ori Elkayam; Daniele Bendayan; Refael Segal; Yinon Shapira; Boris Gilburd; Sandra Reuter; Nancy Agmon-Levin; Yehuda Shoenfeld
Journal:  Rheumatol Int       Date:  2012-08-04       Impact factor: 3.580

3.  Granulomatous Disorder With Pulmonary and Renal Involvement: A Diagnostic and Therapeutic Dilemma.

Authors:  Merina Khan; Nida Saleem; Syed Nayer Mahmud; Muhammad Haneef; Hadia Bukhari
Journal:  Cureus       Date:  2022-03-14

Review 4.  Glomerular disease in patients with infectious processes developing antineutrophil cytoplasmic antibodies.

Authors:  Konstantin N Konstantinov; Suzanne N Emil; Marc Barry; Susan Kellie; Antonios H Tzamaloukas
Journal:  ISRN Nephrol       Date:  2013-02-19

5.  A case report of granulomatous polyangiitis complicated by tuberculous lymphadenitis.

Authors:  Yuki Iijima; Yoichi Kobayashi; Yoshinori Uchida; Toshiharu Tsutsui; Yumiko Kakizaki; Tsukasa Naganuma; Katsuhiko Tsukamoto; Toshio Oyama; Yoshihiro Miyashita
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

6.  Case for diagnosis. Cutaneous small vessel vasculitis (anti-proteinase 3 positive), fever, hemoptysis, and lung cavitation in an adult.

Authors:  Luana Moraes Campos; Mariana Righetto de Ré; Priscila Neri Lacerda; Hélio Amante Miot
Journal:  An Bras Dermatol       Date:  2021-01-30       Impact factor: 1.896

7.  Pulmonary granulomas in a patient with positive ANCA and history of tuberculosis: case report.

Authors:  B Wong; E Tan; A McLean-Tooke
Journal:  BMC Pulm Med       Date:  2020-08-14       Impact factor: 3.317

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.